Drug Discovery and Development
Employees: 11-50
Total raised: $222M
Founded date: 2008
Investors 1
| Date | Name | Website |
| - | The Column... | thecolumng... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 26.07.2022 | Series D | $160M | - |
| 30.09.2020 | Series C | $47M | - |
| 18.01.2018 | - | $15M | - |
Mentions in press and media 8
| Date | Title | Description |
| 25.05.2023 | Carmot Therapeutics Raises $150 Million in Series E | - |
| 25.05.2023 | Carmot Therapeutics Raises $150 Million in Series E Equity Financing to Advance its Pipeline of Treatments for Obesity and Diabetes | - |
| 26.07.2022 | Carmot Therapeutics Raises $160M in Series D Funding | Carmot Therapeutics, Inc., a Berkeley, CA-based clinical-stage biotechnology company applying its proprietary drug discovery platform, Chemotype Evolution, to discover and develop disease-modifying therapies in metabolic disease and cancer,... |
| 26.07.2022 | Carmot Therapeutics Raises $160M Series D | BERKELEY, CA, Carmot Therapeutics announced today a $160 million Series D financing round. >> Click here for more funding data on Carmot Therapeutics >> To export Carmot Therapeutics funding data to PDF and Excel, click here... |
| 30.09.2020 | Carmot Therapeutics Closes $47M Series C Financing | Carmot Therapeutics, Inc., a Berkeley, CA-based biotechnology company focused on bringing transformative therapies to patients with metabolic diseases, raised $47m in series C financing. Amgen joined existing investors, The Column Group and... |
| 18.01.2018 | Carmot Therapeutics Secures $15M in Financing | Carmot Therapeutics, Inc., a Berkeley, California-based biotech company dedicated to the discovery and development of innovative therapeutics generated through Chemotype Evolution, secured $15m in financing. The round was led by Horizons Ve... |
| - | The Column Group Raises a $725 Million Fourth Fund | The Column Group (TCG), a biotech venture capital firm focused on building innovative drug discovery companies, announced the closing of The Column Group IV (TCG IV) and its related investment vehicles totaling $725 million. With TCG IV, th... |
| - | Carmot Therapeutics: Disease-Modifying Therapy Company Raises $150 Million In Series E | Carmot Therapeutics – a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases – recently announced a $150 million oversubscribed and up-sized Series E financing. This financing round was led by D... |